← Russell 3000 cross-section

BLCO Bausch & Lomb Corp

Trailing twelve months to 2026-06-30 · as filed 2026-07-29, not restated
Healthcare

Scale

Market cap
$6.1bn
Revenue TTM
$5.3bn
Net income TTM
$-171m
Free cash flow
$137m
Composite score
41.1
Sector rank
#958

Valuation

P / E
EV / EBITDA
EV / sales
2.0
FCF yield
2.25%
Earnings yield vs 10-yr
-7.54pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-3.2%
EBITDA margin
ROE
-2.7%
ROIC
2.9%
Revenue growth
8.8%

Insider activity, last 90 days

Net open-market
$-1.19m
Buyers
0
Sellers
2

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Our revenues attributable to Russia, Ukraine and Belarus, in the aggregate, were approximately 3% of our total revenues for both the six months ended June 30, 2026 and year ended December 31, 2025. Our revenues attributable to the impacted regions for the six months ended June 30, 2026 and year ended December 31, 2025 were approximately 2% of our total revenues in each period. Under Pillar Two, the Inclusive Framework has agreed on a global minimum corporate tax rate of 15% for companies with revenue above €750 million, calculated on a country-by-country basis. Contract service revenue is derived primarily from contract manufacturing for third parties and is not material. …Bausch & Lomb Corp, 10-Q, period ended 2026-06-30, filed 2026-07-29

Read the full passage →